Nova Leap Health (CVE:NLH) Insider Christopher Thomas Francis Leblanc Buys 50,000 Shares

Nova Leap Health Corp. (CVE:NLHGet Free Report) insider Christopher Thomas Francis Leblanc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were acquired at an average cost of C$0.38 per share, with a total value of C$19,000.00. Following the completion of the purchase, the insider directly owned 369,900 shares in the company, valued at C$140,562. The trade was a 15.63% increase in their position.

Christopher Thomas Francis Leblanc also recently made the following trade(s):

  • On Friday, June 5th, Christopher Thomas Francis Leblanc purchased 2,471 shares of Nova Leap Health stock. The shares were acquired at an average cost of C$0.36 per share, with a total value of C$889.56.

Nova Leap Health Price Performance

Shares of NLH stock opened at C$0.37 on Tuesday. Nova Leap Health Corp. has a 52-week low of C$0.22 and a 52-week high of C$0.44. The company has a debt-to-equity ratio of 14.80, a quick ratio of 1.13 and a current ratio of 1.02. The firm has a market capitalization of C$32.31 million, a P/E ratio of 123.33 and a beta of 1.96. The stock has a 50 day moving average price of C$0.37 and a 200 day moving average price of C$0.33.

Nova Leap Health Company Profile

(Get Free Report)

Nova Leap Health Corp., together with its subsidiaries, provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and skilled nursing care, respite care, cooking and meal preparation, bathing, dressing, grooming, housekeeping, errands, transportation, and medication reminders. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

See Also

Receive News & Ratings for Nova Leap Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nova Leap Health and related companies with MarketBeat.com's FREE daily email newsletter.